For instance, the diminished efficacy of the I1/2 inhibitor in BRAF-mutated CRC is mostly linked to enhanced MAP kinase pathway-independent mechanisms involving EGFR signaling or the PTEN-PI3K-AKT signaling axis [109, 265, 266]. This evidence concerns the gene BRAF and colorectal carcinoma.